2024 AANN Amplify Symposium: Neuro-Oncology-2024 Amplify Neuro Oncology Recording

Video Transcription

Video Summary

The AANN and Amplify Virtual Symposium opened with announcements about continuing-education evaluations, award nominations, research abstracts, and upcoming conferences.<br /><br />Dr. Brad Benin discussed palliative care as support that can begin at diagnosis and continue alongside active treatment, distinguishing it from hospice. He emphasized whole-person quality of life, symptom relief, and structured communication for difficult conversations. Practical guidance included assessing understanding, allowing time for emotion, respecting patient preferences and decision-making capacity, and involving family and other support providers. He also noted that low-dose morphine can relieve severe breathlessness.<br /><br />Dr. Sarah Bach explained how modern brain-tumor classification combines microscopic findings with molecular testing. Markers such as IDH mutations, 1p/19q codeletion, MGMT promoter methylation, and BRAF alterations can refine diagnosis, prognosis, and treatment selection, though testing may add cost and delay.<br /><br />Dr. Sean Mahes reviewed clinical-trial developments in malignant brain tumors. For newly diagnosed glioblastoma, standard care includes maximal safe surgery, radiation, temozolomide, and, in some cases, tumor-treating fields. Ongoing research explores chemotherapy combinations, immunotherapy, and repeat radiation. For brain metastases, trials are comparing radiation strategies, including pre- versus postoperative radiosurgery, stereotactic radiosurgery versus whole-brain radiation, and hippocampal avoidance with memantine to reduce cognitive effects. Speakers highlighted the importance of individualized care, clinical-trial access, and ongoing research.

Keywords

AANN

Amplify Virtual Symposium

palliative care

hospice

whole-person quality of life

symptom relief

brain tumor classification

molecular testing

IDH mutations

1p/19q codeletion

glioblastoma

clinical trials

stereotactic radiosurgery

hippocampal avoidance